Scientific Presentations

ADLM | July 2026

Increase in serum galactose-deficient IgA1 level measured by new lectin-ELISA predicts progression to kidney failure in adults with IgA nephropathy

ERA | June 2026

Increase in Serum Galactose-Deficient IgA1 Level Measured by New LectinELISA Predicts Progression to Kidney Failure in Adults with IgA Nephropathy.

ERA | June 2026

GalD Assay Indicates that Gd-IgA1 Levels Do Not Correlate with Serum Total IgA Levels in IgA Nephropathy Patients.

IIgANN | September 2025

Serum galactose-deficient IgA1 levels in patients with IgA nephropathy and healthy controls measured with the GalD® Assay, a novel lectin-based enzyme-linked immunosorbent assay.

Press Release

July 2026

Reliant Glycosciences to Present Clinical Data from Standardized Assay for IgA Nephropathy Biomarker at ADLM 2026

April 2026

Reliant Glycosciences to Present Landmark IgAN Biomarker Data at ERA 2026 Congress in Glasgow

December 2023

Reliant Glycosciences, supported by the innovate Alabama Supplemental Grant, host events for patients with IgA Nephropathy

October 2021

UAB Biotech Startup, Reliant Glycosciences, Enables Treatment for IgA Nephropathy

News

June 2026

Alabama’s BIO International delegation to promote state’s investment, opportunities 

May 2026

UAB spinout developing laboratory tools for patients with IgA nephropathy

October 2025

Huntsville companies among latest recipients of Innovate Alabama grants

October 2025

Innovate Alabama Invests in 13 Companies Driving Growth in Alabama’s Priority Sectors

November 2024

Commerce trade team leads Alabama mission to MEDICA in Germany

January 2024

Meet Alabama Inno's Startups to Watch for 2024

December 2022

101 Best Alabama Medical Companies and Startups

October 2022

Growing Birmingham company developing assays, talks next steps

October 2022

How the SBIR and STTR Extension Act benefits Birmingham

September 2022

Reliant Glycosciences, Awarded One of the First Innovate Alabama Supplemental Grants in the State of Alabama

June 2022

Birmingham biotech company receives $1.2M toward research